

Ivytan announced on the 11 December, 2008 that the offer to Q-Med's shareholders is withdrawn

Ivytan, indirectly owned by EQT V and Lyftet Holding B.V., a company controlled by Bengt Ågerup, announced on the 11 December, 2008 that the public offer to acquire all shares in Q-Med at SEK 39 per share in cash is withdrawn as the conditions were not satisfied during the acceptance period that ended on Monday 8 December, 2008.

The Independent Board Committee.

Queries should be addressed to:

Pia Rudengren, Chairman of the Board
Mobil: +46 (0)706 242041 or +46 (0)768 161490

***Q-Med AB** is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA**[™], for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane**[®] for filling lines and folds, contouring and creating volume in the face, **Macrolane**[™] for body contouring, **Durolane**[™] for the treatment of osteoarthritis of the hip and knee joints, **Deflux**[®] for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta**[™] for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.*
